Cargando…

Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)

Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availabi...

Descripción completa

Detalles Bibliográficos
Autores principales: AlSaleh, Abdullah, Shahid, Mohammed, Farid, Eman, Kamal, Nermin, Bindayna, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Microbiology Society 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996180/
https://www.ncbi.nlm.nih.gov/pubmed/36910508
http://dx.doi.org/10.1099/acmi.0.000475.v4
_version_ 1784902988147458048
author AlSaleh, Abdullah
Shahid, Mohammed
Farid, Eman
Kamal, Nermin
Bindayna, Khalid
author_facet AlSaleh, Abdullah
Shahid, Mohammed
Farid, Eman
Kamal, Nermin
Bindayna, Khalid
author_sort AlSaleh, Abdullah
collection PubMed
description Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. Material and Methods. Two SCCmec type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCCmec typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. Results and Discussion. Synergy (FIC <0.5) was demonstrated for ascorbic acid (1/2 to 1/4 MIC) with rifampicin (1/2 to 1/8 MIC), and also ascorbic acid (1/2 to 1/16 MIC) when associated with vancomycin (1/2 MIC). Similarly, nicotinamide (1/2 to 1/16 MIC) showed a synergistic effect when paired with low concentrations of rifampicin (1/2 to 1/16 MIC), and also (at 1/4 to 1/16 MIC) with vancomycin (1/2 MIC). All reduced MICs due to synergistic combinations demonstrated statistical significance (P<0.05). Conclusion. The synergistic activity demonstrated in associating antioxidants with antibiotics shows promise in managing superbugs. However, more research is required to better understand the mechanism of the synergy and for utilization in clinical care.
format Online
Article
Text
id pubmed-9996180
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Microbiology Society
record_format MEDLINE/PubMed
spelling pubmed-99961802023-03-10 Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA) AlSaleh, Abdullah Shahid, Mohammed Farid, Eman Kamal, Nermin Bindayna, Khalid Access Microbiol Research Articles Background. Methicillin-resistant Staphylococcus aureus (MRSA) is a pathogenic bacteria involved in a wide spectrum of human diseases. Many virulence factors promote this widespread propagation. One important factor is acquiring antibiotic resistance genes, which leads to a reduction in the availability and efficacy of therapy options. Recently, research has suggested that the remarkable antimicrobial effect of antioxidants against superbugs such as MRSA shows synergistic effects when accompanied by antimicrobial therapy. This paper aims to examine the synergistic effects of ascorbic acid and nicotinamide with a panel of antibiotics used in antimicrobial therapy against MRSA. Material and Methods. Two SCCmec type IV MRSA reference strains (EMRSA-15 and USA300) and 10 MRSA clinical isolates feature in this paper. SCCmec typing was conducted on the 10 clinical isolates via multiplex PCR after identification. Synergy experiments on antioxidants and antibiotics were evaluated via checkerboard assay. The minimum inhibitory concentration (MIC) of each agent was determined in accordance with the Clinical and Laboratory Standards Institute (CLSI) M100 guidelines through twofold microdilution assay. Results and Discussion. Synergy (FIC <0.5) was demonstrated for ascorbic acid (1/2 to 1/4 MIC) with rifampicin (1/2 to 1/8 MIC), and also ascorbic acid (1/2 to 1/16 MIC) when associated with vancomycin (1/2 MIC). Similarly, nicotinamide (1/2 to 1/16 MIC) showed a synergistic effect when paired with low concentrations of rifampicin (1/2 to 1/16 MIC), and also (at 1/4 to 1/16 MIC) with vancomycin (1/2 MIC). All reduced MICs due to synergistic combinations demonstrated statistical significance (P<0.05). Conclusion. The synergistic activity demonstrated in associating antioxidants with antibiotics shows promise in managing superbugs. However, more research is required to better understand the mechanism of the synergy and for utilization in clinical care. Microbiology Society 2023-02-03 /pmc/articles/PMC9996180/ /pubmed/36910508 http://dx.doi.org/10.1099/acmi.0.000475.v4 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License.
spellingShingle Research Articles
AlSaleh, Abdullah
Shahid, Mohammed
Farid, Eman
Kamal, Nermin
Bindayna, Khalid
Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title_full Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title_fullStr Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title_full_unstemmed Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title_short Synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against SCCmec type IV methicillin-resistant Staphylococcus aureus (MRSA)
title_sort synergistic antimicrobial effect of ascorbic acid and nicotinamide with rifampicin and vancomycin against sccmec type iv methicillin-resistant staphylococcus aureus (mrsa)
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996180/
https://www.ncbi.nlm.nih.gov/pubmed/36910508
http://dx.doi.org/10.1099/acmi.0.000475.v4
work_keys_str_mv AT alsalehabdullah synergisticantimicrobialeffectofascorbicacidandnicotinamidewithrifampicinandvancomycinagainstsccmectypeivmethicillinresistantstaphylococcusaureusmrsa
AT shahidmohammed synergisticantimicrobialeffectofascorbicacidandnicotinamidewithrifampicinandvancomycinagainstsccmectypeivmethicillinresistantstaphylococcusaureusmrsa
AT farideman synergisticantimicrobialeffectofascorbicacidandnicotinamidewithrifampicinandvancomycinagainstsccmectypeivmethicillinresistantstaphylococcusaureusmrsa
AT kamalnermin synergisticantimicrobialeffectofascorbicacidandnicotinamidewithrifampicinandvancomycinagainstsccmectypeivmethicillinresistantstaphylococcusaureusmrsa
AT bindaynakhalid synergisticantimicrobialeffectofascorbicacidandnicotinamidewithrifampicinandvancomycinagainstsccmectypeivmethicillinresistantstaphylococcusaureusmrsa